Catalog: | C-FC-3247A |
Product Type: | FCM Antibody |
Size: | 25 Tests/100 Tests |
Concentration: | 10 μl/Test, 0.1 mg/ml |
Reactivity: | Human |
Specificity: | Human E-Cadherin |
Analysis mode: | FCM,ICC/IF |
Host: | Mouse |
Clonality: | Monoclonal |
Isotype: | IgG2a |
Alternate names: | cadherin 1, type 1, E-cadherin (epithelial) |
Form: | Liquid |
Shipping: | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Storage: | This antibody can be stored at 2℃-8℃ for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze ! Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal. |
Purification method: | Protein A |
Conjugation: | FITC |
Immunogen: | Recombinant Human CDH1 protein |
Buffer: | Aqueous solution containing 0.5% BSA and 0.09% sodium azide |
Application: | Hemangioblast Markers; Tumor Suppressors |
Cadherins are calcium-dependent cell adhesion proteins which preferentially interact with themselves in a homophilic manner in connecting cells, and thus may contribute to the sorting of heterogeneous cell type. E-cadherin (E-Cad), also known as CDH1 and CD324, is a calcium-dependent cell adhesion molecule the intact function of which is crucial for the establishment and maintenance of epithelial tissue polarity and structural integrity. Mutations in CDH1 occur in diffuse type gastric cancer, lobular breast cancer, and endometrial cancer. In human cancers, partial or complete loss of E-cadherin expression correlates with malignancy. During apoptosis or with calcium influx, E-Cad is cleaved by the metalloproteinase to produce fragments of about 38 kDa (E-CAD/CTF1), 33 kDa (E-CAD/CTF2) and 29 kDa (E-CAD/CTF3), respectively. E-Cad has been identified as a potent invasive suppressor, as downregulation of E-cadherin expression is involved in dysfunction of the cell-cell adhesion system, and often correlates with strong invasive potential and poor prognosis of human carcinomas.
Copyright © 2025 Creative Biogene. All rights reserved.